Passage Bio, Inc. (PASG)

NCM – Real Time Price. Currency in USD

6.38

-0.51 (-7.40%)

At close: Mar 27, 2026, 4:00 PM EDT

6.21

-0.17 (-2.66%)

After-hours: Mar 27, 2026, 5:36 PM EDT

About the company

Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; PBGM01, a functional GLB1 gene encoding β-galactosidase for infantile GM1; and PBKR03, for the treatment of Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other programs for huntington’s disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania’s Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is based in Philadelphia, Pennsylvania.

Key Executives

Name	Position
Dr. Karl Whitney Ph.D.	Senior Vice President of Global Regulatory Affairs
Dr. Sue Browne Ph.D.	Chief Scientific Officer
Dr. William Chou M.D.	President, CEO & Director
Mr. Eden Fucci	Senior Vice President of Technical Operations
Mr. Stuart M. Henderson	Chief Business Officer
Ms. Kathleen Borthwick	Senior VP, CFO, Principal Financial Officer & Principal Accounting Officer